Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway

Anti-Cancer Drugs

Volumn 19, Issue 6, 2008, Pages 553-563

  Newcomb, Elizabeth W ^a   Lukyanov, Yevgeniy ^a   Smirnova, Iva ^a   Schnee, Tona ^a   Zagzag, David ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University School of Medicine   (United States)

Author keywords

Apoptosis; Apoptosis inducing factor dependent pathway; Bcl 2 phosphorylation; Noscapine; Tubulin binding agent

Indexed keywords

APOPTOSIS INDUCING FACTOR; BETA ACTIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE SYNTHASE; NOSCAPINE; PROTEIN BAX; PROTEIN BCL 2; RAF PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; CYCLIN B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ENZYME INACTIVATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; CELL DIVISION; DRUG EFFECT; GLIOMA; PATHOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYTOCHROMES C; GLIOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; NOSCAPINE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 53749106421     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282ffd68d     Document Type: Article

References (56)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665-667.
2. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3:193-203.
3. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22:9075-9086.
4. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8:413-450.
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-265.
6. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006; 54:72-84.
7. Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1α expression and angiogenesis in vitro: a novel function for an old drug. Int J Oncol 2006; 28:1121-1130.
8. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, et al.Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 1998; 95:1601-1606.
9. Mahmoudian M, Mehrpour M, Benaissa F, Siadatpour Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur J Clin Pharmacol 2003; 59:579-581.
10. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002; 277: 17200-17208.
11. Mooraki A, Jenabi A, Jabbari M, Zolfaghari MI, Javanmardi SZ, Mahmoudian M, et al.Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough. Nephrology (Carlton) 2005; 10:348-350.
12. Mahmoudian M, Mojaverian N. Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the guinea-pig. Acta Physiol Hung 2001; 88:231-237.
13. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006; 69:1801-1809.
14. Heidari N, Goliaei B, Moghaddam PR, Rahbar-Roshandel N, Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 2007; 18:1139-1147.
15. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49:217-225.
16. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, et al.Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62:4109-4114.
17. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, et al.Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004; 10:5187-5201.
18. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EMO11. Blood 2006; 107: 2486-2492.
19. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, et al.Rationale design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 2006; 66:3782-3791.
20. Tulpule A, Levine AM, Berman NE, Smith L, Auerbach A, Douer D. Phase I study of noscapine for patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia refractory to chemotherapy. Blood 2005; 106:3341.
21. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2:139-150.
22. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, et al.Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1a) in glioma cell invasion. J Cell Physiol 2003; 196:394-402.
23. Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol 2004; 201:374-384.
24. Newcomb EW, Ali MA, Schnee T, Lan L, Lukyanov Y, Fowkes M, et al.Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1a expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncol 2005; 7:225-235.
25. Newcomb EW, Lymberis SC, Lukyanov Y, Shao Y, Schnee T, Devitt ML, et al.Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle 2006; 5:93-99.
26. Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, et al.The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs 2007; 18:875-882.
27. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
28. Leverrier S, Bergamaschi D, Ghali L, Ola A, Warnes G, Akgul B, et al.Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis 2007; 12:549-560.
29. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci U S A 1983; 80:2926-2930.
30. Muehlbauer PA, Schuler MJ. Measuring the mitotic index in chemically-treated human lymphocyte cultures by flow cytometry. Mutat Res 2003; 537:117-130.
31. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56:1253-1255.
32. Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 2000; 60:3425-3428.
33. Ling Y-H, Jiang J-D, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002; 62:529-538.
34. Kolfschoten GM, Hulscher TM, Duyndam MCA, Pinedo HM, Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 2002; 63:733-743.
35. Borgne A, Meijer L. Sequential desphosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem 1996; 271:27847-27854.
36. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, et al.Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115:575-585.
37. 2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002; 43:39777-39785.
38. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, et al.Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999; 274:8208-8216.
39. Weiderhold KN, Randall-Hlubek DA, Polin LA, Hamel E, Mooberry SL. CB694, a novel antimitotic with antitumor activities. Int J Cancer 2006; 118:1032-1040.
40. Shtil AA, Mandlekar S, Yu R, Walter RJ, Hagen K, Tan TH, et al.Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 1999; 18:377-384.
41. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254:110-119.
42. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quade JC Jr, et al.Taccalonlides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003; 63:3211-3220.
43. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007; 67:3862-3870.
44. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-2837.
45. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al.Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007; 14:1237-1266.
46. Aneja R, Dhiman N, Idnani J, Awasthe A, Arora SK, Chandra R, et al.Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007; 60: 831-839.
47. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-1331.
48. Ambrose M, Ryan A, O'Sullivan GC, Dunne C, Barry OP. Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38δ/γ, cycloooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol Pharmacol 2006; 69:1879-1890.
49. Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M. The role of ERK 1/2 and p38MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001; 268:84-92.
50. Mansilla S, Priebe W, Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 2006; 5:53-60.
51. Gao N, Rahmani M, Dent P, Grant S. 2-methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005; 24:3793-3809.
52. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al.OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID, and AIF-dependent killing of transformed cells. Mol Pharmaol 2006; 70:589-603.
53. Srivastava RK, Mi Q-S, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A 1999; 96:3775-3780.
54. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)M. Mol Cell Biol 1999; 19:8469-8478.
55. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993; 4:327-332.
56. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519.